Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Cantabio Pharmaceuticals Inc (EM) CTBO

Healthcare Biotechnology
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company. The Company is focused on commercializing therapies and the intellectual property generated from its research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. The Company’s small molecule therapy candidates program (CB101) and protein therapy... see more

Current News (EXPM:CTBO)

Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate to Research the Therapeutic targeting of the DJ-1 Protein to Treat Immune Associated Diseases

ACCESS Newswire October 21, 2019

Cantabio Pharmaceuticals to Present Latest Positive In Vivo Results From its DJ-1 Targeting Small Molecule Drug Development Program for Parkinson’s Disease at the Milner Therapeutics Symposium at the University of Cambridge, UK

GlobeNewswire October 1, 2018

Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Results in a Mice Model of Parkinson’s disease of One of Its Orally Administered Novel DJ-1 Protein Targeting Therapeutic Candidates at the XXV International Symposium on Medicinal Chemistry in

GlobeNewswire July 31, 2018

Cantabio Announces Publication of Study on Druggability of the Tau protein in ACS Chemical Neuroscience

GlobeNewswire June 28, 2018

Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Data in a Mice Model of Parkinson’s disease from Its DJ-1 Protein Targeting Therapeutic Program at the Neuro4D Conference in Mainz, Germany

GlobeNewswire May 9, 2018

Cantabio Pharmaceuticals to Present Results from its Tau Protein Targeting Therapeutic Program for the treatment of Alzheimer's Disease at the Advances in Alzheimer's and Parkinson's Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy

MarketWire Canada February 26, 2018

Cantabio Pharmaceuticals to Present Update from Its DJ-1 Protein Targeting Therapeutic Program for the Treatment of Parkinson's Disease at Advances in Alzheimer's and Parkinson's Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy

MarketWire Canada January 22, 2018

Cantabio Pharmaceuticals to Present at 2017 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai

Marketwired September 13, 2017

Cantabio announces publication of study on a mechanism by which the DJ-1 protein loses its defensive function in neurodegenerative disease conditions

MarketWire Canada September 11, 2017
View More News ››

Opinion & Analysis (EXPM:CTBO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:CTBO)

Be the first to post on this bullboard.

DRC Gold Corp.

DRC Gold Corp.

DRC Gold Corp. is an exploration and development company formed for the purposes of acquiring, exploring and if warranted and ...
View More »

Podcasts